DK1597282T3 - Antistofmolekyler, der har specificitet for human IL-1 beta - Google Patents

Antistofmolekyler, der har specificitet for human IL-1 beta

Info

Publication number: DK1597282T3
Authority: DK; Denmark
Prior art keywords: specificity; beta; human; antibody molecules; antibody
Prior art date: 2003-02-13

Application number

DK04708808.3T

Other languages

English (en)

Inventor

Alastair D G Lawson

Andrew G Popplewell

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-13

Filing date

2004-02-06

Publication date

2012-01-23

2004-02-06 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2012-01-23 Application granted granted Critical

2012-01-23 Publication of DK1597282T3 publication Critical patent/DK1597282T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Transplantation (AREA)
Plant Pathology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)

DK04708808.3T 2003-02-13 2004-02-06 Antistofmolekyler, der har specificitet for human IL-1 beta DK1597282T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0303337.0A GB0303337D0 (en)	2003-02-13	2003-02-13	Biological products
PCT/GB2004/000463 WO2004072116A2 (en)	2003-02-13	2004-02-06	ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-1β

Publications (1)

Publication Number	Publication Date
DK1597282T3 true DK1597282T3 (da)	2012-01-23

Family

ID=9952969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04708808.3T DK1597282T3 (da)	2003-02-13	2004-02-06	Antistofmolekyler, der har specificitet for human IL-1 beta

Country Status (26)

Country	Link
US (2)	US7608694B2 (da)
EP (2)	EP1597282B1 (da)
JP (2)	JP4668896B2 (da)
KR (1)	KR20050099509A (da)
CN (1)	CN1745103A (da)
AR (1)	AR043159A1 (da)
AT (1)	ATE525397T1 (da)
AU (1)	AU2004210776B2 (da)
BR (1)	BRPI0407233A (da)
CA (1)	CA2515474C (da)
CL (1)	CL2004000259A1 (da)
CY (1)	CY1112507T1 (da)
DK (1)	DK1597282T3 (da)
EA (1)	EA200501286A1 (da)
EC (1)	ECSP056014A (da)
ES (1)	ES2373953T3 (da)
GB (1)	GB0303337D0 (da)
IS (1)	IS8013A (da)
MX (1)	MXPA05007392A (da)
NO (1)	NO20054223L (da)
PE (1)	PE20040947A1 (da)
PL (1)	PL378412A1 (da)
PT (1)	PT1597282E (da)
SI (1)	SI1597282T1 (da)
TW (1)	TW200505942A (da)
WO (1)	WO2004072116A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
JP5102028B2 (ja)	2004-07-26	2012-12-19	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗ｃｄ１５４抗体
EP1851245B1 (en)	2005-01-26	2012-10-10	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
PT1899378E (pt)	2005-06-21	2010-01-26	Xoma Technology Ltd	Anticorpos de ligação de il-1β e os seus fragmentos
GB0513852D0 (en) *	2005-07-06	2005-08-10	Celltech R&D Ltd	Biological products
PL1940465T3 (pl) *	2005-10-26	2013-01-31	Novartis Ag	Nowe zastosowanie przeciwciał anty-IL-1beta
NZ569234A (en)	2005-12-09	2011-07-29	Ucb Pharma Sa	Antibody molecules having specificity for human IL-6
GB0612928D0 (en) *	2006-06-29	2006-08-09	Ucb Sa	Biological products
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
US7695718B2 (en)	2006-12-20	2010-04-13	Xoma Technology Ltd.	Methods for the treatment of IL-1β related diseases
EP2125894B1 (en)	2007-03-22	2018-12-19	Biogen MA Inc.	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
ES2660036T3 (es)	2007-12-07	2018-03-20	Zymogenetics, Inc.	Moléculas de anticuerpo humanizadas específicas para IL-31
HRP20141194T1 (hr)	2007-12-20	2015-04-24	Xoma (Us) Llc	Postupci lijeäśenja gihta
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
EA201001691A1 (ru)	2008-04-28	2011-10-31	Калобайос Фармасьютикалз, Инк.	Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
WO2010028275A1 (en)	2008-09-05	2010-03-11	Xoma Technology Ltd.	METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
BRPI1008692B8 (pt) *	2009-02-17	2021-05-25	Ucb Biopharma Sprl	anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
SI2993231T1 (sl)	2009-09-24	2018-10-30	Ucb Biopharma Sprl	Bakterijski sev za izražanje rekombinantnega proteina, ki ima proteazno deficientno DEGP-zadrževalno šaperonsko aktivnost, ter onesposobljena gena TSP in PTR
AR078650A1 (es) *	2009-10-15	2011-11-23	Abbott Lab	Anticuerpo de union a il-1 beta
GB201000590D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial host strain
GB201000591D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial hoist strain
GB201000587D0 (en)	2010-01-14	2010-03-03	Ucb Pharma Sa	Bacterial hoist strain
EA201201526A1 (ru)	2010-05-07	2013-06-28	Ксома Текнолоджи Лтд.	Способы лечения состояний, связанных с il-1b
PL2571532T3 (pl) *	2010-05-14	2017-10-31	Abbvie Inc	Białka wiążące IL-1
GB201012599D0 (en)	2010-07-27	2010-09-08	Ucb Pharma Sa	Process for purifying proteins
US8465413B2 (en)	2010-11-25	2013-06-18	Coloplast A/S	Method of treating Peyronie's disease
ES2632583T3 (es)	2011-01-14	2017-09-14	Ucb Biopharma Sprl	Anticuerpo que se une a IL-17A e IL-17F
WO2013007388A1 (en)	2011-07-13	2013-01-17	Ucb Pharma, S.A.	Bacterial host strain expressing recombinant dsbc
UA112203C2 (uk)	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2794657B1 (en)	2011-12-19	2017-10-11	Xoma (Us) Llc	Methods for treating acne
WO2013122544A2 (en)	2012-02-13	2013-08-22	Agency For Science, Technology And Research	IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2013157105A1 (ja) *	2012-04-18	2013-10-24	公立大学法人大阪市立大学	ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) *	2012-04-18	2013-10-24	公立大学法人大阪市立大学	ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
GB201208367D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Biological product
WO2014011955A2 (en)	2012-07-12	2014-01-16	Abbvie, Inc.	Il-1 binding proteins
CN104341501B (zh) *	2013-07-29	2019-08-30	上海睿智化学研究有限公司	抗IL-1β人源化单克隆抗体及其制备方法和应用
AU2015207464B2 (en)	2014-01-20	2019-10-03	Eveon	Process for reconstitution of a solid form of a pharmaceutical composition
GB201501613D0 (en)	2015-01-30	2015-03-18	Ucb Biopharma Sprl	Treatment of autoimmune disorders with CD154 antibodies
US9560393B2 (en) *	2015-02-20	2017-01-31	Disney Enterprises, Inc.	Media processing node
CN106349388B (zh) *	2015-07-17	2021-04-02	上海佳文英莉生物技术有限公司	一种促细胞程序性坏死抗体及其应用
MY206805A (en)	2015-10-27	2025-01-08	UCB Biopharma SRL	Methods of treatment using anti-il-17a/f antibodies
GB201616596D0 (en)	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies
CN110818793A (zh) *	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
CN113383016B (zh) *	2018-11-07	2022-09-13	三生国健药业（上海）股份有限公司	结合人IL-1β的抗体、其制备方法和用途
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
IL303294A (en)	2020-12-07	2023-07-01	UCB Biopharma SRL	Antibodies against interleukin-22
AU2021395729A1 (en)	2020-12-07	2023-07-13	UCB Biopharma SRL	Multi-specific antibodies and antibody combinations
CA3218933A1 (en)	2021-05-03	2022-11-10	UCB Biopharma SRL	Antibodies
GB202111905D0 (en)	2021-08-19	2021-10-06	UCB Biopharma SRL	Antibodies
CN113855807A (zh) *	2021-10-25	2021-12-31	孙良丹	一种试剂在制备治疗/抑制银屑病药物中的应用
CN114524875B (zh) *	2021-11-11	2023-07-25	江苏莱森生物科技研究院有限公司	偶联IL-1β单克隆抗体的纳米硅球及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB129105A (en)	1918-07-02	1919-07-02	Alfred George Hubble	Improvements in and connected with Closing Means for Milk Churns, Containers and Vessels.
EP0569687B1 (en)	1984-05-18	2002-08-21	New England Medical Center Hospitals, Inc.	Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
US4935343A (en)	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
US5474899A (en) *	1987-05-13	1995-12-12	Cistron Biotechnology, Inc.	Selective immunoassay for IL-1 β
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0813423B1 (en)	1995-01-23	2002-07-03	Xenotech Incorporated	Composition to inhibit osteolysis and metastasis
JPH09183799A (ja) *	1995-11-06	1997-07-15	Merck Patent Gmbh	ヒト化モノクローナル抗体
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9720054D0 (en) *	1997-09-19	1997-11-19	Celltech Therapeutics Ltd	Biological products
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
GB0013810D0 (en) *	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
US20030026806A1 (en) *	2000-10-27	2003-02-06	Amgen Inc.	Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
EP1423432A4 (en) *	2001-07-26	2006-01-11	Lilly Co Eli	ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products

2003
- 2003-02-13 GB GBGB0303337.0A patent/GB0303337D0/en not_active Ceased
2004
- 2004-02-06 AT AT04708808T patent/ATE525397T1/de active
- 2004-02-06 WO PCT/GB2004/000463 patent/WO2004072116A2/en not_active Ceased
- 2004-02-06 EA EA200501286A patent/EA200501286A1/ru unknown
- 2004-02-06 KR KR1020057013813A patent/KR20050099509A/ko not_active Withdrawn
- 2004-02-06 AU AU2004210776A patent/AU2004210776B2/en not_active Ceased
- 2004-02-06 CA CA2515474A patent/CA2515474C/en not_active Expired - Fee Related
- 2004-02-06 BR BR0407233-2A patent/BRPI0407233A/pt not_active Application Discontinuation
- 2004-02-06 EP EP04708808A patent/EP1597282B1/en not_active Expired - Lifetime
- 2004-02-06 DK DK04708808.3T patent/DK1597282T3/da active
- 2004-02-06 PT PT04708808T patent/PT1597282E/pt unknown
- 2004-02-06 SI SI200431797T patent/SI1597282T1/sl unknown
- 2004-02-06 CN CNA2004800033654A patent/CN1745103A/zh active Pending
- 2004-02-06 US US10/544,911 patent/US7608694B2/en not_active Expired - Fee Related
- 2004-02-06 ES ES04708808T patent/ES2373953T3/es not_active Expired - Lifetime
- 2004-02-06 JP JP2006502246A patent/JP4668896B2/ja not_active Expired - Fee Related
- 2004-02-06 EP EP10182246A patent/EP2287193A1/en not_active Withdrawn
- 2004-02-06 MX MXPA05007392A patent/MXPA05007392A/es not_active Application Discontinuation
- 2004-02-06 PL PL378412A patent/PL378412A1/pl unknown
- 2004-02-09 PE PE2004000142A patent/PE20040947A1/es not_active Application Discontinuation
- 2004-02-12 AR ARP040100431A patent/AR043159A1/es unknown
- 2004-02-12 TW TW093103340A patent/TW200505942A/zh unknown
- 2004-02-12 CL CL200400259A patent/CL2004000259A1/es unknown
2005
- 2005-09-07 IS IS8013A patent/IS8013A/is unknown
- 2005-09-12 NO NO20054223A patent/NO20054223L/no unknown
- 2005-09-13 EC EC2005006014A patent/ECSP056014A/es unknown
2009
- 2009-09-29 US US12/569,700 patent/US8465744B2/en not_active Expired - Fee Related
2010
- 2010-06-04 JP JP2010128372A patent/JP2010246553A/ja active Pending
2011
- 2011-12-21 CY CY20111101274T patent/CY1112507T1/el unknown

Also Published As

Publication number	Publication date
MXPA05007392A (es)	2005-09-12
AR043159A1 (es)	2005-07-20
NO20054223D0 (no)	2005-09-12
CA2515474A1 (en)	2004-08-26
JP2010246553A (ja)	2010-11-04
JP2007515925A (ja)	2007-06-21
AU2004210776A1 (en)	2004-08-26
US7608694B2 (en)	2009-10-27
CY1112507T1 (el)	2015-12-09
CA2515474C (en)	2013-11-12
US20060228358A1 (en)	2006-10-12
CL2004000259A1 (es)	2005-04-15
US20100158913A1 (en)	2010-06-24
PE20040947A1 (es)	2004-12-29
CN1745103A (zh)	2006-03-08
EP2287193A1 (en)	2011-02-23
GB0303337D0 (en)	2003-03-19
EP1597282B1 (en)	2011-09-21
AU2004210776B2 (en)	2011-04-07
EA200501286A1 (ru)	2006-02-24
WO2004072116A2 (en)	2004-08-26
SI1597282T1 (sl)	2012-02-29
ATE525397T1 (de)	2011-10-15
PL378412A1 (pl)	2006-04-03
TW200505942A (en)	2005-02-16
KR20050099509A (ko)	2005-10-13
IS8013A (is)	2005-09-07
JP4668896B2 (ja)	2011-04-13
ES2373953T3 (es)	2012-02-10
NO20054223L (no)	2005-11-08
PT1597282E (pt)	2012-01-05
WO2004072116A3 (en)	2004-11-18
EP1597282A2 (en)	2005-11-23
US8465744B2 (en)	2013-06-18
BRPI0407233A (pt)	2006-01-31
ECSP056014A (es)	2006-01-27

Publication	Publication Date	Title
DK1597282T3 (da)	2012-01-23	Antistofmolekyler, der har specificitet for human IL-1 beta
IL242434B (en)	2018-04-30	Antibody molecules with selectivity for 6-il of human origin
EP1890653A4 (en)	2011-09-07	SPACER FOR SPINACH APOPHYSIS
DE602004000756D1 (de)	2006-06-01	Doppelköderstation für insekten
FR2871075B1 (fr)	2015-09-11	Catalyseur
DE602004026768D1 (de)	2010-06-02	Therapeutische anti-igfr1-antikörper-kombinationen
IS2693B (is)	2010-11-15	Fenoxýediksýruafleiður
DK1879623T3 (da)	2012-12-17	Genterapi til rygmarvssygdomme
EP1716505A4 (en)	2009-10-21	PARALLEL DATABASES WITHOUT SHARING
ATE400206T1 (de)	2008-07-15	Ausziehführungsgarnitur für schubladen
DE602004011446D1 (de)	2008-03-13	Kleiderbügel für Strickware
EP1903334A4 (en)	2011-12-21	BIOSENSOR
DE502004002610D1 (de)	2007-02-22	Biozid-wirksame Kombination für landwirtschaftliche Anwendungen
EP1725269A4 (en)	2009-04-22	Catalytic radiofluorination
DE502004008190D1 (de)	2008-11-20	Schalldämpfer
EP1909098A4 (en)	2010-08-11	BIOSENSOR
DE602004031650D1 (de)	2011-04-14	Drehbund für hubsäge
DE60324848D1 (de)	2009-01-02	Ausgleichsmechanismus für drehwelle
DE602004001142D1 (de)	2006-07-27	Schalldämpfer
DE602006009980D1 (de)	2009-12-10	Biosensor
DE04291076T1 (fr)	2005-05-04	Sitz für verkehrsmittel, inbesondere lufttransporte
DE502004008685D1 (de)	2009-01-29	Fadenführervorrichtung für ringspindel
NL1023270A1 (nl)	2004-02-24	Bestratingselement.
DE602005010664D1 (de)	2008-12-11	Katalytische asymmetrische epoxydierung
ITVE20050020U1 (it)	2006-12-11	Pettine parapasseri